Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

NCT00292071 ↗

Phase 2 Completed 16 enrolled Merck Sharp & Dohme LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.

Timeline

Start: 2004-05
Primary completion: 2006-07
Completion: 2006-07

Publications

Background Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009 Apr;53(4):1450-6. doi: 10.1128/AAC.01027-08. Epub 2008 Dec 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Caspofungin	Other / unclassified	50 mg/m2	Intravenous
Subject	Caspofungin	Other / unclassified	70 mg/m2	Intravenous

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Summary

Timeline

Publications

Drugs

Indications